Thrombolytic

Phase 3Small molecule

FFaculty Hospital Kralovske Vinohrady

Thrombolytic is one of 67 small molecule programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

Pulmonary EmbolismRecruiting

COVID-19Preclinical

Active, not recruiting

Pulmonary EmbolismPhase 3

Recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

Thrombolytic

FFaculty Hospital Kralovske Vinohrady

Phase 3

1 2

Aldactone

Pfizer

Preclinical

1 3

Nexavar

Bayer

Preclinical

1 4

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 5

Tricor

JJagotec

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Benadryl

PParkedale

Preclinical

1 8

Nitrostat

VViatris Specialty LLC

Preclinical

1 9

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 10

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalRecruiting

Pulmonary Embolism

NCT05493163

Clinical

Trials by Indication[1]

STEMI1 trial

The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI

Withdrawn·—··NCT03267199

Pulmonary Embolism1 trial

Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism

Recruiting·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT05493163·558 enrolled

COVID-191 trial

Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak.

Unknown status·YYa-Wei Xu·N/A·NCT05354128·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Thrombolytic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thrombolytic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thrombolytic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Faculty Hospital Kralovske Vinohrady company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFaculty Hospital Kralovske Vinohrady

Thrombolytic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

STEMI1 trial

Pulmonary Embolism1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News